menu-iconMore mobile-close-icon
Skip Navigation
Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC

Announcements

April 16, 2012

Health Awareness Topics - April 2012



NGC Spotlight


New research review, clinician and consumer guides added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.

Conference News


The Guidelines International Network (G-I-N) Conference 2012, will be held August 22-25, 2012 in Berlin, Germany. Registration External Web Site Policy is now open.

U.S. Food and Drug Administration (FDA) Advisory


  • April 10, 2012: Birth Control Pills Containing Drospirenone External Web Site Policy: FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills.Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.

NGC's Sister Resources